公开(公告)号：US20240173434A1

公开(公告)日：2024-05-30

申请号：US18385310

申请日：2023-10-30

Applicant: CRISPR THERAPEUTICS AG ,  BAYER HEALTHCARE LLC

Inventor： Alan Richard Brooks

IPC: A61K48/00 ,  A61K9/00 ,  A61K9/127 ,  A61K9/51 ,  A61P7/04 ,  C07K14/755 ,  C12N9/22 ,  C12N15/113

CPC classification number: A61K48/0058 ,  A61K9/0019 ,  A61K9/127 ,  A61K9/51 ,  A61K48/0066 ,  A61K48/0075 ,  A61P7/04 ,  C07K14/755 ,  C12N9/22 ,  C12N15/113 ,  C12N2310/20

Abstract: Provided include materials and methods for treating Hemophilia A in a subject ex vivo or in vivo. Also provided include materials and methods for knocking in a FVIII-encoding gene in a genome, in particular the locus of albumin gene.

公开(公告)号：US11992557B2

公开(公告)日：2024-05-28

申请号：US16963648

申请日：2019-01-23

Applicant: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED

Inventor： Avi Schroeder ,  Assaf Zinger

IPC: A61K9/127 ,  A61K31/337 ,  A61K38/48 ,  A61P35/00

CPC classification number: A61K9/127 ,  A61K9/1277 ,  A61K31/337 ,  A61K38/4886 ,  A61P35/00 ,  C12Y304/24007

Abstract: Pharmaceutical compositions comprising at least one lipid-based particle encapsulating a proteolytic enzyme and a pharmaceutically acceptable carrier, wherein the proteolytic enzyme comprises at least 75% proteolytically active enzyme are provided. Methods of using same and producing same are also provided.

公开(公告)号：US11986527B2

公开(公告)日：2024-05-21

申请号：US16174023

申请日：2018-10-29

Applicant: BAUSCH HEALTH IRELAND LIMITED

Inventor： Arturo Angel ,  Gordon Dow

IPC: A61K47/14 ,  A61K9/00 ,  A61K9/06 ,  A61K9/107 ,  A61K9/127 ,  A61K9/14 ,  A61K31/573 ,  A61K31/58 ,  A61P17/06

CPC classification number: A61K47/14 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/107 ,  A61K9/127 ,  A61K31/573 ,  A61K31/58 ,  A61P17/06

Abstract: Pharmaceutical compositions for topical application to skin are provided. In some embodiments, the pharmaceutical compositions comprise a corticosteroid and further comprise a liquid oil component comprising one or more dicarboxylic acid esters and/or monocarboxylic acid esters.

公开(公告)号：US20240156905A1

公开(公告)日：2024-05-16

申请号：US18283108

申请日：2022-03-30

Applicant: KAINOS MEDICINE, INC.

Inventor： Eunhee KIM ,  Jeong-Hoon HAN

IPC: A61K38/17 ,  A61K9/127 ,  A61P35/00 ,  C12N5/071 ,  C12N5/09 ,  G01N33/50

CPC classification number: A61K38/1761 ,  A61K9/127 ,  A61P35/00 ,  C12N5/0686 ,  C12N5/0693 ,  G01N33/5011 ,  C12N2510/00

Abstract: Fas-associated factor 1 (FAF1) protein-loaded exosomes and a cancer treatment using FAF1 protein-loaded exosomes are disclosed. FAF1 protein-loaded exosomes are isolated from HEK 293 cells in which FAF1 having a known tumor-suppressive function is overexpressed and administered the FAF1 protein-loaded exosomes to various tumor models in which pancreatic cancer cells (MIA PaCa-2), lung cancer cells (A549), colon cancer cells (HCT 116), liver cancer cells (Hep3B), breast cancer cells (MDA-MB-231), kidney cancer cells (Caki-1) and cervical cancer cell (HeLa cell) are transplanted into nude mice through intratumoral injection. The administration exhibited tumor growth inhibitory effects remarkably greater than those of a control group not treated with FAF1.

公开(公告)号：US11980634B2

公开(公告)日：2024-05-14

申请号：US18481951

申请日：2023-10-05

Applicant: MOLECULIN BIOTECH, INC. ,  Board of Regents, The University of Texas System

Inventor： Donald Picker ,  Waldemar Priebe

IPC: A61K31/704 ,  A61K9/00 ,  A61K9/127

CPC classification number: A61K31/704 ,  A61K9/0019 ,  A61K9/127

Abstract: Methods of reconstituting lyophilized Annamycin and methods of treating patients are described.

公开(公告)号：US20240150355A1

公开(公告)日：2024-05-09

申请号：US18540129

申请日：2023-12-14

Applicant: ASTRAZENECA AB ,  CANCER RESEARCH TECHNOLOGY LIMITED

Inventor： Maurice Raymond Verschoyle FINLAY ,  Frederick Woolf GOLDBERG ,  Martin Richard HOWARD ,  Attilla Kuan Tsuei TING

IPC: C07D473/32 ,  A61K9/127 ,  A61K31/437 ,  A61K31/502 ,  A61K31/522 ,  A61K31/5377 ,  A61K31/704

CPC classification number: C07D473/32 ,  A61K9/127 ,  A61K31/437 ,  A61K31/502 ,  A61K31/522 ,  A61K31/5377 ,  A61K31/704 ,  A61N5/10

Abstract: The specification generally relates to compounds of Formula (I):




and pharmaceutically acceptable salts thereof, where R1, A1, A2 and A3 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent DNA-PK mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating DNA-PK mediated disease, including cancer, using such compounds and salts.

公开(公告)号：US20240141357A1

公开(公告)日：2024-05-02

申请号：US18546414

申请日：2022-02-14

Applicant: THE UNIVERSITY OF BRITISH COLUMBIA

Inventor： Christian J. Kastrup ,  Amy W. Strilchuk ,  Jerry Leung ,  Pieter R. Cullis ,  Madelaine Robertson

IPC: C12N15/113 ,  A61K9/127 ,  A61K47/14 ,  A61K47/24 ,  A61K47/28 ,  A61P7/04

CPC classification number: C12N15/1137 ,  A61K9/127 ,  A61K47/14 ,  A61K47/24 ,  A61K47/28 ,  A61P7/04 ,  C12N2310/14

Abstract: The present disclosure provides a duplex or single-stranded siRNA molecule against plasminogen, the siRNA molecule containing modified or unmodified nucleotides and wherein at least one strand of the duplex or the single-stranded siRNA has a sequence that has at least 80% sequence identity to any one of SEQ NOs: 1 to 28. Further provided is a duplex or single-stranded siRNA molecule against plasminogen, the siRNA molecule containing modified or unmodified nucleotides and is between 25 and 35 nucleotides in length. The siRNA molecule may be formulated in a lipid nanoparticle as described herein.

公开(公告)号：US11969504B2

公开(公告)日：2024-04-30

申请号：US17888862

申请日：2022-08-16

Applicant: Mantra Bio, inc.

Inventor： Terry Gaige ,  Colin David Gottlieb

IPC: A61K9/127 ,  A61K9/00 ,  A61K47/69 ,  C07K14/705 ,  C12N15/62 ,  C12N15/63

CPC classification number: A61K9/127 ,  A61K9/0019 ,  A61K47/6901 ,  C07K14/705 ,  C12N15/62 ,  C12N15/63

Abstract: Disclosed herein are non-naturally occurring vesicle comprising a chimeric vesicle localization moiety comprising a surface-and-transmembrane domain of a first vesicle localization moiety and a cytosolic domain of a second vesicle localization moiety, the method of making said vesicle and uses thereof.

公开(公告)号：US11969501B2

公开(公告)日：2024-04-30

申请号：US17405990

申请日：2021-08-18

Applicant: DOMPÉ FARMACEUTICI S.P.A.

Inventor： Jay Lichter ,  Andrew M. Trammel ,  Fabrice Piu ,  Qiang Ye ,  Michael Christopher Scaife ,  Benedikt Vollrath ,  Sergio G. Duron ,  Luis A. Dellamary ,  Carl Lebel ,  Jeffrey P. Harris

IPC: A61K9/00 ,  A61K9/06 ,  A61K9/127 ,  A61K9/14 ,  A61K9/16 ,  A61K31/05 ,  A61K31/13 ,  A61K31/137 ,  A61K31/325 ,  A61K31/43 ,  A61K31/436 ,  A61K31/519 ,  A61K31/5513 ,  A61K31/5517 ,  A61K38/18 ,  A61K47/14 ,  A61K47/18 ,  A61K47/32 ,  A61K47/38 ,  C07K16/24 ,  A61K39/00

CPC classification number: A61K9/0046 ,  A61K9/06 ,  A61K9/127 ,  A61K9/14 ,  A61K9/16 ,  A61K31/05 ,  A61K31/13 ,  A61K31/137 ,  A61K31/325 ,  A61K31/43 ,  A61K31/436 ,  A61K31/519 ,  A61K31/5513 ,  A61K31/5517 ,  A61K38/18 ,  A61K38/1808 ,  A61K38/1825 ,  A61K38/185 ,  A61K38/1858 ,  A61K38/1883 ,  A61K47/14 ,  A61K47/18 ,  A61K47/32 ,  A61K47/38 ,  C07K16/241 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/76

Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or auris interna target areas, or via perfusion into the auris media and/or auris interna structures.

公开(公告)号：US11964050B2

公开(公告)日：2024-04-23

申请号：US16043126

申请日：2018-07-23

Applicant: Pharmosa Biopharm Inc.

Inventor： Pei Kan ,  Yi Fong Lin ,  Ko Chieh Chen

IPC: A61K9/127 ,  A61K31/5585 ,  A61K47/02 ,  A61P11/06

CPC classification number: A61K9/127 ,  A61K9/1271 ,  A61K9/1278 ,  A61K31/5585 ,  A61K47/02 ,  A61P11/06

Abstract: The present invention relates to a pharmaceutical composition comprising a weak acid drug, with the use of a bicarbonate salt to achieve a high incorporation of the drug into the liposome and a better therapeutic efficacy. Also disclosed is a method for treating a respiratory disease using the pharmaceutical composition disclosed herein.